Functional characterization of blood cell associated regulatory GWAS hits

Information

  • Research Project
  • 9263659
  • ApplicationId
    9263659
  • Core Project Number
    R33HL120752
  • Full Project Number
    7R33HL120752-04
  • Serial Number
    120752
  • FOA Number
    RFA-HL-13-027
  • Sub Project Id
  • Project Start Date
    3/5/2014 - 10 years ago
  • Project End Date
    2/28/2019 - 5 years ago
  • Program Officer Name
    QASBA, PANKAJ
  • Budget Start Date
    6/7/2016 - 8 years ago
  • Budget End Date
    2/28/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    04
  • Suffix
  • Award Notice Date
    6/7/2016 - 8 years ago

Functional characterization of blood cell associated regulatory GWAS hits

ABSTRACT The vast majority (>90%) of disease- and trait-associated variants emerging from genome-wide association studies (GWAS) lie in non-coding regions of the genome, and currently all but a handful lack molecular mechanisms that explain the observed associations with complex traits. Superimposition of the human regulatory DNA catalogue with GWAS data reveals a striking concentration of disease-associated variation precisely within regulatory DNA regions defined by DNaseI hypersensitive sites. We will fully understand gene regulation and mis-regulation only if we are able to examine genetic variants in their biological chromatin context in otherwise isogenic cells. TALE nuclease (TALEN) platforms can alter the DNA sequence of cells in a precise, targeted manner. We have already established the feasibility of single-TALEN- mediated homologous recombination for efficient knockout of individual regulatory DNA regions. In R21 phae, we will model candidate disease/trait-associated variants in regulatory DNA in vivo using engineered templates at 10 individual regulatory regions. We will test the feasibility and determine the salient operating characteristics of a scalable implementation of a TALEN genomic modification pipeline using K562 cells, and demonstrate knockout feasibility and specific allele insertion in primary hematopoietic cells and document efficiencies. We will test the efficiency of a using single or multiple TALENs flanking an editing site. In the R33 pahse, we will scale the TALEN pipeline process to efficiently characterize sites identified in GWAS studies as associated with red blood cell phenotypes.. These studies will provide a direct proof for the role of regulatory elements and demonstrate the relevance of GWAS associated SNPs as causative for the observed phenotypes.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R33
  • Administering IC
    HL
  • Application Type
    7
  • Direct Cost Amount
    386881
  • Indirect Cost Amount
    36027
  • Total Cost
    422908
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:422908\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZHL1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES
  • Organization Department
  • Organization DUNS
    079715609
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981213622
  • Organization District
    UNITED STATES